Ponatinib is a third generation BCR-ABL kinase inhibitor which was created to counter the T315I gatekeeper mutation which causes imatinib resistance in patients with CML [68]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.